Piper Sandler Raises Price Target on AbbVie (ABBV) Amid Strong IBD Pipeline Progress

AbbVie Inc. (NYSE:ABBV) ranks among the best retirement stocks to buy now. Piper Sandler increased its price target for AbbVie Inc. (NYSE:ABBV) to $298 from $294 on May 14, retaining an Overweight rating on the company’s shares. The firm mentioned AbbVie’s extensive inflammatory bowel disease pipeline as a major source of investor interest.

Pixabay/Public Domain

AbbVie Inc. (NYSE:ABBV) submitted 18 abstracts on inflammatory bowel illnesses at the 2026 Digestive Disease Week Annual Meeting, which was held in Chicago from May 2 to 5. The research centered around real-world evidence and long-term results for the company’s Crohn’s disease and ulcerative colitis therapies, SKYRIZI and RINVOQ.

The presentation featured 52-week follow-up results from the ASPIRE-CD study, which demonstrated that risankizumab-treated individuals with moderately to highly active Crohn’s disease had long-lasting improvements in liquid stools, bowel urgency, and abdominal pain.

Piper Sandler stated that management’s pursuit of novel combination methods in IBD is a positive development, considering the competitiveness of the IBD medication development landscape. According to the firm, one factor that makes AbbVie Inc. (NYSE:ABBV) appealing is the variety of R&D shots-on-goal that stay beneath the radar of the general investment market.

AbbVie Inc. (NYSE:ABBV) is a research-based biopharmaceutical company that researches & develops, manufactures, commercializes, and sells medicines and therapies worldwide.

While we acknowledge the risk and potential of BAC as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than BAC and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1